Has Susan Tate, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,452 in general payments to Susan Tate, MD across 111 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Tate, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Tate, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Tate, MD

Urogynecology and Reconstructive Pelvic Surgery · Louisville, KYNPI 1811913585

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,018 of the $2,452 with a category attached, or 82.3%. It is spread thinly across 28 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $459 and has fallen 52.6% since, to $218 in 2025.

$2,452in general payments, 2019–2025

Across 111 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astellas Pharma US Inc$356
Medtronic$289
AbbVie$174
Amneal Pharmaceuticals LLC$154
UCB, Inc.$146
Sanofi$141
plus $1K from 22 others

What the payments were for

Speaking & faculty fees$994%
Food & beverage$2,01882%
Education$33614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astellas Pharma US Inc	6	$356
Medtronic(2 entities)	10	$289
AbbVie	7	$174
Amneal Pharmaceuticals LLC	8	$154
UCB, Inc.	6	$146
Sanofi	7	$141
Acorda Therapeutics, Inc	9	$128
Teva Pharmaceuticals USA, Inc.	8	$118
Amgen	7	$118
Lundbeck LLC	5	$88
Supernus Pharmaceuticals, Inc.	6	$84
Baxter Healthcare	1	$71
Eisai Inc.	4	$69
Axonics, Inc.	2	$57
EMD Serono, Inc.	4	$57
Adamas Pharmaceuticals, Inc.	3	$52
SK Life Science, Inc.	2	$49
Catalyst Pharmaceuticals, Inc.	2	$40
Aquestive Therapeutics, Inc.	2	$40
Avion Pharmaceuticals	2	$39
Biogen	2	$35
AstraZeneca	2	$32
CSL Behring	1	$27
Pfizer	1	$25
Grifols USA, LLC	1	$18
Impel Pharmaceuticals Inc.	1	$17
Boston Scientific	1	$15
Johnson & Johnson	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INTERSTIM$127

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$95,643

Medicare patients

137

Services billed

732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
GemtesaVibegron	26	$25,466
Estradiol	52	$3,037
Clobetasol Propionate	24	$1,880
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	63	$393
Hydroxyzine Hcl	59	$272
CefuroximeCefuroxime Axetil	16	$168
Doxycycline Hyclate	15	$116
Ibuprofen	32	$88
Oxycodone Hcl	24	$69
Promethazine Hcl	27	$65
Cephalexin	11	$49

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Louisville

Sarah KaneLouisville$5K
Jenna WarehimeLouisville$4K
Majorie PilkintonLouisville$3K
Andrew DoeringLouisville$2K
Susan OakleyEdgewood$23K
Parisa SamimiBowling Green$9K
Shubham GuptaLexington$8K
Caroline Elmer-LyonEdgewood$7K
Gerardo Heredia MeleroLexington$4K
Kurt JaenickeLouisa$134

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →